DNMT1 antibody | knockout validation | Cell Signaling 5032

This is a knockout-validated antibody summary, based on the publication "MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

DNMT1 antibody | knockout validation | Cell Signaling 5032 figure 1
Figure 1. Immunoblotting analysis to measure DNMT1 knockdown in protein levels in BT-549 (left) and HCC1143 (right) cells. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: DNMT1

Catalog number: 5032

Summary: Rabbit monoclonal antibody against a synthetic peptide corresponding to residues surrounding Leu985 of human DNMT1 protein. Reacts with human, mouse, rat, and monkey. It is predicted to react based on 100% sequence homology with hamster, bovine, dog, horse, and guinea pig. Suitable for western blot, immunohistochemistry (paraffin), immunofluorescence/immunocytochemistry and flow cytometry.

Validation Method

Western blot

Sample

Control and DNMT1-KO BT-549 and HCC1143 cells.

Primary incubation

1:1,000 dilution.

Detection

Enhanced chemiluminescence system (Bio-Rad, Molecular Imager ChemiDOC XRS+).

References
  1. Wu S, Xiao Y, Wei J, Xu X, Jin X, Hu X, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer. 2021;9: pubmed publisher